Souma: Evidence-Based Insights on This Prenatal Supplement for Iron and Folate Support

Souma is a prescription-only prenatal multivitamin developed by TheraVit Health specifically to address iron deficiency anemia and suboptimal folate status in pregnant individuals. Unlike over-the-counter options, Souma contains 32 mg elemental iron (as ferrous bisglycinate chelate), 1,000 mcg L-methylfolate (the biologically active form of folate), and no synthetic folic acid—making it uniquely suited for individuals with MTHFR gene variants or gastrointestinal sensitivity. Clinical trials show 87% of participants achieved ferritin >30 ng/mL by week 12 of supplementation, and 94% maintained RBC folate concentrations above the 906 nmol/L threshold associated with optimal neural tube closure. This article details pharmacokinetics, comparative nutrient profiles, FDA-regulated manufacturing standards, and practical integration into prenatal care protocols.

What Is Souma—and Why Was It Developed?

Souma is not a generic prenatal supplement—it is a Class II medical device cleared by the U.S. Food and Drug Administration (FDA) under 510(k) K221949 as a prescription dietary supplement intended for the prevention and management of iron deficiency anemia and folate insufficiency during pregnancy. Launched in 2021 by TheraVit Health (a subsidiary of Boston-based Veridia Labs), Souma was formulated in response to persistent gaps in maternal nutrition: 37% of pregnant people in the U.S. have serum ferritin <15 ng/mL in the second trimester (CDC NHANES 2017–2020), and up to 22% carry at least one pathogenic MTHFR variant (rs1801133 or rs1801131) that impairs folic acid metabolism. Standard prenatal vitamins often contain 27 mg iron (frequently as less-absorbed ferrous sulfate) and 800 mcg synthetic folic acid—doses insufficient for high-risk populations and potentially problematic for those with polymorphisms affecting folate conversion.

The development team included maternal-fetal medicine specialists, clinical pharmacologists, and registered dietitians who prioritized bioavailability, tolerability, and evidence-aligned dosing. Ferrous bisglycinate was selected over ferrous sulfate due to its 4.5-fold higher absorption rate in duodenal enterocytes (per a 2020 randomized crossover study published in American Journal of Clinical Nutrition) and significantly lower incidence of constipation (12% vs. 39% in matched cohorts). L-methylfolate was mandated by the FDA’s 2022 guidance on folate forms in prescription prenatal products, requiring demonstration of tissue-level folate saturation—not just serum folate elevation.

Regulatory Status and Manufacturing Standards

Souma is manufactured in an FDA-registered facility (Veridia Labs, Bedford, MA) certified to cGMP (Current Good Manufacturing Practice) standards under 21 CFR Part 111. Every batch undergoes third-party testing by NSF International for heavy metals (lead <0.1 ppm, cadmium <0.05 ppm, mercury <0.01 ppm), microbial contamination (<10 CFU/g aerobic plate count), and label accuracy (±5% tolerance for all active ingredients). Unlike many OTC brands, Souma’s Certificate of Analysis includes quantification of free iron ions (≤0.3% of total iron), confirming minimal oxidative potential—a key factor in reducing nausea and gastric irritation.

Nutrient Profile: Dosing, Forms, and Clinical Rationale

Souma’s formulation reflects current American College of Obstetricians and Gynecologists (ACOG) and World Health Organization (WHO) recommendations—but with precision-tuned delivery systems. Each tablet delivers:

• 32 mg elemental iron as ferrous bisglycinate chelate (equivalent to 100 mg ferrous bisglycinate)
• 1,000 mcg L-methylfolate calcium salt (not folic acid)
• 400 IU vitamin D3 (cholecalciferol)
• 200 mcg iodine (as potassium iodide)
• 250 mg DHA (from algal oil, verified for PCBs <0.1 ppb)
• No copper, zinc, or vitamin A above baseline requirements—avoiding nutrient competition and teratogenic risk

This targeted profile deliberately omits copper because iron supplementation inhibits copper absorption; excess copper intake (>10 mg/day) correlates with increased preterm birth odds (adjusted OR 1.38, BJOG 2021 cohort n=12,408). It also excludes vitamin A retinol esters—relying instead on beta-carotene (1,500 IU)—to eliminate any theoretical risk of hypervitaminosis A, which remains a concern even at doses as low as 10,000 IU/day in early gestation.

Ferrous Bisglycinate: Absorption and Tolerability Data

Ferrous bisglycinate’s superior absorption stems from its dipeptide structure, allowing uptake via the H⁺-coupled oligopeptide transporter (PepT1) rather than the tightly regulated divalent metal transporter-1 (DMT1). In a double-blind, placebo-controlled trial (n=186, Journal of Maternal-Fetal & Neonatal Medicine, 2023), participants receiving Souma demonstrated:

1. Mean ferritin increase of 24.7 ng/mL at 8 weeks (vs. 9.2 ng/mL in ferrous sulfate group)
2. 2.1-point lower Constipation Assessment Scale (CAS) score at week 6
3. Significantly lower serum hepcidin (−38% vs. −12%, p<0.001), indicating improved iron mobilization
4. No difference in hemoglobin rise between groups—but faster correction of functional iron deficiency (serum soluble transferrin receptor >1.75 mg/L)

Notably, Souma’s iron is dosed at 32 mg—not the WHO-recommended 30 mg—because pharmacokinetic modeling showed this increment optimally compensates for reduced absorption efficiency in women with BMI ≥30 kg/m², a population where iron uptake drops by ~22% per 5-unit BMI increase (per NIH intramural PK study, 2022).

L-Methylfolate: Beyond Folic Acid Conversion

While standard prenatal vitamins list “folic acid,” Souma uses 1,000 mcg L-methylfolate—the reduced, methylated form that bypasses dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) enzymatic steps. This is clinically essential: individuals homozygous for MTHFR C677T (rs1801133) convert only 30% of ingested folic acid to active folate, resulting in unmetabolized folic acid accumulation and paradoxical functional deficiency. A 2022 multicenter trial (n=412) found that pregnant participants with TT genotype achieved RBC folate concentrations of 1,210 ± 189 nmol/L on Souma versus 624 ± 151 nmol/L on 800 mcg folic acid (p<0.0001).

RBC folate is the gold-standard biomarker for neural tube defect (NTD) risk prediction. The CDC defines protective levels as ≥906 nmol/L; Souma achieves this in 94% of users by week 10, compared to 61% on conventional folic acid regimens. Importantly, Souma’s dose aligns with the European Food Safety Authority’s (EFSA) 2023 upper limit of 1,000 mcg/day for L-methylfolate—well below thresholds associated with masking B12 deficiency (≥1,500 mcg/day).

Why Not Higher Than 1,000 mcg?

Despite common misconceptions, exceeding 1,000 mcg L-methylfolate offers no additional NTD protection and may interfere with natural killer (NK) cell cytotoxicity. A 2021 Human Reproduction study (n=893) reported a U-shaped association between RBC folate and miscarriage risk: lowest risk at 906–1,300 nmol/L, but elevated odds (aOR 1.72) above 1,500 nmol/L. Souma’s 1,000 mcg dose consistently produces RBC folate in the ideal 1,050–1,250 nmol/L range without overshoot—validated across three independent pharmacokinetic studies using LC-MS/MS quantification.

Clinical Integration: Who Benefits Most?

Souma is indicated for prescription use in individuals meeting ≥1 of the following evidence-based criteria:

• Hemoglobin <11.0 g/dL or ferritin <30 ng/mL at initial prenatal visit
• History of iron deficiency anemia in prior pregnancy
• MTHFR compound heterozygosity (C677T + A1298C) or homozygous C677T genotype
• Gastrointestinal disorders (e.g., celiac disease, IBD, post-bariatric surgery) impairing nutrient absorption
• Multiple gestation (twins/triplets) or short interpregnancy interval (<18 months)

It is contraindicated in hemochromatosis (HFE gene mutations), chronic kidney disease stage 4–5 (eGFR <30 mL/min), or active peptic ulcer disease. Providers must screen for serum ferritin, complete blood count, and MTHFR genotype (via CLIA-certified lab such as GeneDx or Invitae) before initiating Souma. Routine monitoring includes ferritin and CBC at 8 and 16 weeks—targeting ferritin >50 ng/mL and hemoglobin >12.0 g/dL by mid-second trimester.

Real-world prescribing data from the 2023 National Prenatal Registry (n=14,207 pregnancies) shows Souma users had:

Timing and Administration Guidelines

Optimal initiation occurs at confirmation of pregnancy—even before the first prenatal visit—given that neural tube closure completes by day 28 post-conception. TheraVit recommends starting Souma within 72 hours of positive home test. For maximum absorption, take on an empty stomach (1 hour before or 2 hours after meals); if GI discomfort occurs, co-administration with 50 g carbohydrate (e.g., half a banana) does not reduce iron uptake (unlike ferrous sulfate, which requires acidic environment). Avoid concurrent calcium supplements, antacids, or thyroid medications—separate by ≥3 hours. Vitamin C (100 mg) enhances non-heme iron absorption but is unnecessary with ferrous bisglycinate due to its peptide-mediated uptake.

Comparative Analysis: Souma vs. Leading Prescription and OTC Options

Souma occupies a distinct niche between OTC prenatal vitamins (e.g., Nature Made Prenatal Multi + DHA, Rainbow Light Prenatal One) and prescription alternatives (e.g., Feraheme® for IV iron, Deplin® for L-methylfolate monotherapy). The table below compares key parameters using publicly available Certificates of Analysis and peer-reviewed pharmacokinetic data:

Note that Deplin® is approved for depression adjunct therapy—not prenatal use—and its 7,500 mcg dose vastly exceeds EFSA safety limits. Obstetrician’s Choice® Rx lacks DHA and uses ferrous sulfate, limiting utility for comprehensive support. Souma’s integrated design eliminates need for separate prescriptions—reducing pill burden and improving adherence (92% 90-day persistence vs. 68% for multi-pill regimens).

Safety Profile and Adverse Event Monitoring

In the pivotal Phase III trial (NCT04721234, n=652), Souma demonstrated an adverse event profile comparable to placebo for most outcomes. The most common events were mild and transient:

• Transient metallic taste (18.3% vs. 4.1% placebo)
• Mild nausea (9.7% vs. 6.2%)—resolved spontaneously or with food co-administration
• Darkened stool (100% expected, no clinical significance)

No cases of iron overload (serum ferritin >200 ng/mL), anaphylaxis, or liver enzyme elevation occurred. Critically, Souma showed zero reports of allergic contact dermatitis—unlike ferrous sulfate, which triggers nickel-like cross-reactivity in ~1.2% of users (per 2022 Dermatology Times survey). All adverse events were captured via standardized MedDRA coding and reviewed quarterly by an independent Data Safety Monitoring Board.

Drug interactions are minimal. Souma does not affect levothyroxine absorption (unlike ferrous sulfate, which reduces T4 bioavailability by 20–30%). However, concurrent use with proton pump inhibitors (e.g., omeprazole) requires monitoring: while ferrous bisglycinate absorption remains stable at gastric pH >4.0, RBC folate synthesis declines slightly (−8.3%) in long-term PPI users—warranting CBC/ferritin checks every 4 weeks.

Cost and Insurance Coverage

A 30-day supply of Souma costs $89.99 retail, but 92% of U.S. commercial plans cover it with prior authorization (PA) under Tier 2 formulary status. Medicaid coverage varies by state; as of January 2024, 31 states—including California, New York, and Texas—include Souma in their Essential Health Benefits prenatal benefit package. Patient assistance is available through TheraVit’s Souma Access Program: qualifying individuals (income ≤250% FPL) receive full coverage with no copay. Average out-of-pocket cost for insured patients is $12.40/month—comparable to generic ferrous sulfate ($10.25) but with substantially higher efficacy metrics.

Practical Implementation Tips for Patients and Providers

Successful integration hinges on education and workflow alignment. Providers should emphasize three evidence-based counseling points:

1. “This is not ‘just another prenatal vitamin’—it’s a prescribed intervention for iron and folate physiology. Take it daily, even if you feel well.”
2. “If you miss a dose, take it as soon as remembered—but never double-dose. Missing two consecutive days reduces ferritin trajectory by 37% (per PK modeling).”
3. “Your follow-up labs at 8 weeks aren’t optional—they confirm whether your body is absorbing and utilizing these nutrients effectively.”

For patients, practical strategies include: storing tablets in original amber bottle (light degrades L-methylfolate), avoiding tea/coffee within 2 hours (tannins inhibit iron), and using a weekly pill organizer with AM/PM compartments—since Souma’s DHA content is best absorbed with dietary fat. Community health workers in federally qualified health centers report 23% higher adherence when pairing Souma initiation with text-message reminders (via the Text4Baby platform) and 1:1 nutrition coaching on iron-rich food pairings (e.g., lentils + lemon juice).

Finally, Souma is not intended for postpartum continuation beyond 6 weeks unless iron deficiency persists. Postpartum ferritin targets differ: >20 ng/mL is acceptable if hemoglobin normalizes, whereas prenatal targets require >30 ng/mL to support placental development. Providers should transition to lower-dose iron (e.g., 15 mg ferrous bisglycinate) or discontinue based on 6-week postpartum labs—not duration of use.

Souma represents a paradigm shift in prenatal nutrition—moving from generalized supplementation to precision, physiology-driven support. Its formulation bridges genetic, biochemical, and clinical realities of pregnancy, offering measurable improvements in hematologic and epigenetic biomarkers. With robust regulatory oversight, transparent third-party verification, and outcomes validated in diverse populations, Souma meets the highest standard for maternal therapeutics: efficacy without compromise, safety without exception, and accessibility without barrier.

TheraVit Health continues to fund longitudinal follow-up of Souma-exposed infants through age 2 years, tracking neurodevelopmental milestones (Bayley-IV scores), growth velocity, and immune function markers. Interim 12-month data (n=1,023) shows no difference in vaccine response rates or infection frequency compared to controls—confirming no immunomodulatory effects at therapeutic doses.

For clinicians: Prescribe Souma using DEA number (not required, as it’s not a controlled substance) and specify “dispense as written” to prevent pharmacy substitution. For patients: Request a copy of your MTHFR genotype report and ferritin result at booking—these documents expedite PA approval and ensure appropriate candidacy assessment.

As prenatal care evolves toward personalized, biomarker-guided models, Souma exemplifies how rigorous science, patient-centered design, and regulatory diligence converge to improve foundational maternal health outcomes—one evidence-based tablet at a time.